Type 2 diabetes
Conditions
Interventions
Insulin icodec is initiated at a dose of 1 unit/kg and titrated every two weeks according to the protocol, based on pre-breakfast blood glucose levels. The pre-breakfast blood glucose value is defined
Sponsors
Kansai Rousai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who are able to provide written informed consent to participate in the study of their own free will. 2) Patients who meet the diagnostic criteria for type 2 diabetes mellitus. 3) Patients aged 20 years or older at the time informed consent is obtained. 4) Patients for whom insulin dose adjustment every two weeks after intervention is feasible.
Exclusion criteria
Exclusion criteria: 1) Patients with contraindications to insulin icodec used in this study. 2) Patients with active malignancy. 3) Patients with severe hepatic or renal impairment that may affect the safety evaluation of the study drug. 4) Women who are pregnant or may be pregnant. 5) Breastfeeding women. 6) Patients receiving treatment with oral systemic corticosteroids. 7) Patients deemed ineligible by the principal investigator or sub-investigators for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time in weeks to achieve target glycemic levels | — |
Countries
Japan
Contacts
Public ContactTsunehiko Yamamoto
Kansai Rousai Hospital Department of Diabetes and Endocrinology
Outcome results
None listed